Delisting riskPopularity #2,803
Akebia Therapeutics (AKBA)
Markets kidney-disease medicines while advancing rare-renal and HIF programs.
$0.9750
After hours+0.00 (+0.13%)
At close$0.9737(+3.75%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42 | 56 | 33 | 44 | 37 | 46 | 57 | 62 | 59 | 58 | 54 | 49 |
| Cost of revenue | 18 | 19 | 3 | 8 | 14 | 20 | 8 | 10 | 10 | 12 | 13 | 10 |
| Gross profit | 24 | 38 | 30 | 35 | 23 | 26 | 50 | 53 | 49 | 45 | 41 | 39 |
| 37 | 36 | 45 | 44 | 36 | 40 | 36 | 38 | 45 | 54 | 46 | 45 | |
| Research & development | 13 | 10 | 10 | 8 | 8 | 12 | 10 | 11 | 15 | 27 | 15 | 14 |
| 23 | 25 | 0 | 0 | 27 | 28 | 26 | 27 | 30 | 26 | 30 | 28 | |
| Selling & marketing | 23 | 25 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 23 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other expenses | 1 | 1 | 35 | 36 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 3 |
| Operating income | −13 | 1 | −15 | −9 | −13 | −14 | 14 | 14 | 4 | −9 | −5 | −6 |
| −1 | −1 | −3 | 0 | −8 | −8 | −7 | −14 | −3 | −3 | −4 | −3 | |
| Interest expense | 1 | 1 | 2 | 2 | 7 | 7 | 8 | 7 | 5 | 5 | −5 | 3 |
| Other non-operating income | 0 | −1 | −1 | −1 | 1 | 2 | 0 | 7 | −1 | −2 | 9 | −1 |
| Income before tax | −14 | 1 | −18 | −9 | −20 | −23 | 6 | 0 | 1 | −11 | −9 | −9 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Net income from continuing operations | −14 | 1 | −18 | −9 | −20 | −23 | 6 | 0 | 1 | −12 | −9 | −9 |
| Net income | −14 | 1 | −18 | −9 | −20 | −23 | 6 | 0 | 1 | −12 | −9 | −9 |
| EPS, basic | −$0.08 | $0.00 | −$0.09 | −$0.04 | −$0.10 | −$0.10 | $0.03 | $0.00 | $0.00 | −$0.05 | −$0.03 | −$0.03 |
| EPS, diluted | −$0.08 | $0.00 | −$0.09 | −$0.04 | −$0.10 | −$0.10 | $0.03 | $0.00 | $0.00 | −$0.05 | −$0.03 | −$0.03 |
| Weighted average shares, basic | 188 | 190 | 205 | 210 | 210 | 219 | 235 | 263 | 265 | 265 | 267 | 270 |
| Weighted average shares, diluted | 188 | 190 | 205 | 210 | 210 | 219 | 242 | 271 | 274 | 265 | 267 | 270 |
| EBITDA | −4 | 11 | −5 | 1 | −4 | −7 | 14 | 7 | 6 | −6 | −13 | −5 |
| Depreciation & amortization | 9 | 9 | 9 | 9 | 9 | 9 | 0 | 0 | 0 | 0 | 0 | 1 |
| EBIT | −13 | 2 | −14 | −8 | −13 | −16 | 14 | 7 | 6 | −6 | −14 | −6 |